$27.90
1.194.46%
At close: -
$28.00
0.100.36%
After Hours: Apr 11, 6:08 PM EDT
Comments
Loading...
Ionis Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:IONS | Benzinga
Ionis Pharmaceuticals Inc has a consensus price target of $56.37 based on the ratings of 30 analysts. The high is $88 issued by Wells Fargo on May 4, 2023. The low is $27 issued by SVB Leerink on February 23, 2023. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Redburn Atlantic on April 8, 2025, April 7, 2025, and March 31, 2025, respectively. With an average price target of $48 between Needham, HC Wainwright & Co., and Redburn Atlantic, there's an implied 71.43% upside for Ionis Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Redburn Atlantic
JP Morgan
Citigroup
1calculated from analyst ratings
Analyst Ratings for Ionis Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/07/2025 | Buy Now | 60.71% | HC Wainwright & Co. | Mitchell Kapoor42% | → $45 | Initiates | → Buy | Get Alert |
| 04/03/2025 | Buy Now | — | Guggenheim | Debjit Chattopadhyay48% | — | Reiterates | Buy → Buy | Get Alert |
| 03/31/2025 | Buy Now | 39.29% | Redburn Atlantic | Joshua Smith 13% | → $39 | Initiates | → Neutral | Get Alert |
| 03/24/2025 | Buy Now | 60.71% | JP Morgan | Jessica Fye64% | $47 → $45 | Maintains | Neutral | Get Alert |
| 03/11/2025 | Buy Now | 67.86% | JP Morgan | Jessica Fye64% | $51 → $47 | Maintains | Neutral | Get Alert |
| 02/20/2025 | Buy Now | 128.57% | Citigroup | David Lebowitz52% | $67 → $64 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | 150% | RBC Capital | Luca Issi37% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2025 | Buy Now | 60.71% | BMO Capital | Kostas Biliouris32% | $60 → $45 | Maintains | Market Perform | Get Alert |
| 02/20/2025 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | 150% | RBC Capital | Luca Issi37% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 12/20/2024 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Maintains | Buy | Get Alert |
| 11/14/2024 | Buy Now | 121.43% | Piper Sandler | Allison Bratzel58% | $65 → $62 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 175% | Wells Fargo | Yanan Zhu35% | $82 → $77 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 10/09/2024 | Buy Now | 132.14% | Guggenheim | Debjit Chattopadhyay48% | $70 → $65 | Maintains | Buy | Get Alert |
| 09/26/2024 | Buy Now | 150% | RBC Capital | Luca Issi37% | $70 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 08/26/2024 | Buy Now | 96.43% | JP Morgan | Jessica Fye64% | $50 → $55 | Maintains | Neutral | Get Alert |
| 08/02/2024 | Buy Now | 150% | Guggenheim | Debjit Chattopadhyay48% | $64 → $70 | Maintains | Buy | Get Alert |
| 08/02/2024 | Buy Now | 32.14% | Goldman Sachs | Salveen Richter52% | $33 → $37 | Maintains | Sell | Get Alert |
| 08/02/2024 | Buy Now | 82.14% | Barclays | Gena Wang50% | $45 → $51 | Maintains | Equal-Weight | Get Alert |
| 08/02/2024 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2024 | Buy Now | 114.29% | BMO Capital | Kostas Biliouris32% | $67 → $60 | Downgrade | Outperform → Market Perform | Get Alert |
| 07/24/2024 | Buy Now | 121.43% | Leerink Partners | Mani Foroohar48% | $53 → $62 | Upgrade | Market Perform → Outperform | Get Alert |
| 07/23/2024 | Buy Now | 110.71% | TD Cowen | Yaron Werber34% | $54 → $59 | Maintains | Buy | Get Alert |
| 07/23/2024 | Buy Now | 142.86% | B of A Securities | Jason Gerberry61% | $67 → $68 | Maintains | Buy | Get Alert |
| 07/22/2024 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/16/2024 | Buy Now | 139.29% | B of A Securities | Jason Gerberry61% | $64 → $67 | Maintains | Buy | Get Alert |
| 07/16/2024 | Buy Now | 167.86% | Jefferies | Akash Tewari43% | $29 → $75 | Upgrade | Underperform → Buy | Get Alert |
| 06/27/2024 | Buy Now | 89.29% | Stifel | Paul Matteis42% | $50 → $53 | Maintains | Hold | Get Alert |
| 06/14/2024 | Buy Now | — | Bernstein | William Pickering37% | — | Upgrade | Underperform → Market Perform | Get Alert |
| 06/03/2024 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 192.86% | Wells Fargo | Yanan Zhu35% | $85 → $82 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | — | Wolfe Research | Andy Chen32% | — | Upgrade | Peer Perform → Outperform | Get Alert |
| 04/09/2024 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/09/2024 | Buy Now | 167.86% | Oppenheimer | Jay Olson61% | $72 → $75 | Maintains | Outperform | Get Alert |
| 03/06/2024 | Buy Now | 157.14% | Oppenheimer | Jay Olson61% | $65 → $72 | Maintains | Outperform | Get Alert |
| 02/26/2024 | Buy Now | 132.14% | Oppenheimer | Jay Olson61% | $63 → $65 | Reinstates | → Outperform | Get Alert |
| 02/22/2024 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | Buy Now | 125% | Piper Sandler | Do Kim55% | $62 → $63 | Maintains | Overweight | Get Alert |
| 02/01/2024 | Buy Now | 96.43% | JP Morgan | Jessica Fye64% | $52 → $55 | Maintains | Neutral | Get Alert |
| 01/26/2024 | Buy Now | 150% | RBC Capital | Luca Issi37% | $65 → $70 | Maintains | Outperform | Get Alert |
| 01/18/2024 | Buy Now | 121.43% | Piper Sandler | Do Kim55% | $60 → $62 | Maintains | Overweight | Get Alert |
| 01/02/2024 | Buy Now | 121.43% | B of A Securities | Jason Gerberry61% | $52 → $62 | Upgrade | Neutral → Buy | Get Alert |
| 12/19/2023 | Buy Now | 114.29% | Needham | Joseph Stringer48% | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 12/18/2023 | Buy Now | 78.57% | Stifel | Paul Matteis42% | $45 → $50 | Maintains | Hold | Get Alert |
| 11/17/2023 | Buy Now | 114.29% | Needham | Joseph Stringer48% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | — | Goldman Sachs | Salveen Richter52% | $25 → $28 | Maintains | Sell | Get Alert |
| 11/03/2023 | Buy Now | 71.43% | Morgan Stanley | Michael Ulz58% | $45 → $48 | Maintains | Equal-Weight | Get Alert |
| 10/23/2023 | Buy Now | 85.71% | B of A Securities | Jason Gerberry61% | $33 → $52 | Upgrade | Underperform → Neutral | Get Alert |
| 10/05/2023 | Buy Now | 132.14% | RBC Capital | Luca Issi37% | → $65 | Reiterates | Outperform → Outperform | Get Alert |
| 09/29/2023 | Buy Now | 125% | Raymond James | — | → $63 | Initiates | → Strong Buy | Get Alert |
| 09/27/2023 | Buy Now | 60.71% | Morgan Stanley | Michael Ulz58% | $42 → $45 | Maintains | Equal-Weight | Get Alert |
| 09/27/2023 | Buy Now | 114.29% | Needham | Joseph Stringer48% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | 114.29% | Needham | Joseph Stringer48% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 114.29% | Citigroup | David Lebowitz52% | $36 → $60 | Upgrade | Neutral → Buy | Get Alert |
| 06/07/2023 | Buy Now | 107.14% | Piper Sandler | Do Kim55% | → $58 | Assumes | → Overweight | Get Alert |
| 05/04/2023 | Buy Now | 132.14% | RBC Capital | Luca Issi37% | → $65 | Reiterates | → Outperform | Get Alert |
| 05/04/2023 | Buy Now | 28.57% | Citigroup | David Lebowitz52% | $30 → $36 | Upgrade | Sell → Neutral | Get Alert |
| 05/04/2023 | Buy Now | 214.29% | Wells Fargo | Vanck Zhu75% | $92 → $88 | Maintains | Overweight | Get Alert |
| 05/04/2023 | Buy Now | 32.14% | Barclays | Gena Wang50% | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 05/04/2023 | Buy Now | 114.29% | Needham | Joseph Stringer48% | → $60 | Reiterates | → Buy | Get Alert |
| 04/25/2023 | Buy Now | 114.29% | Needham | Joseph Stringer48% | → $60 | Reiterates | → Buy | Get Alert |
| 04/18/2023 | Buy Now | 114.29% | Needham | Joseph Stringer48% | → $60 | Reiterates | → Buy | Get Alert |
| 04/11/2023 | Buy Now | 50% | Morgan Stanley | Michael Ulz58% | $40 → $42 | Maintains | Equal-Weight | Get Alert |
| 03/21/2023 | Buy Now | 10.71% | Bernstein | William Pickering37% | → $31 | Initiates | → Underperform | Get Alert |
| 02/23/2023 | Buy Now | -3.57% | SVB Leerink | Mani Foroohar48% | $34 → $27 | Maintains | Market Perform | Get Alert |
| 02/23/2023 | Buy Now | 132.14% | RBC Capital | Luca Issi37% | → $65 | Reiterates | → Outperform | Get Alert |
| 02/23/2023 | Buy Now | 139.29% | BMO Capital | Gary Nachman56% | $70 → $67 | Maintains | Outperform | Get Alert |
| 02/23/2023 | Buy Now | 42.86% | Barclays | Gena Wang50% | $44 → $40 | Maintains | Equal-Weight | Get Alert |
| 02/23/2023 | Buy Now | 114.29% | Needham | Joseph Stringer48% | → $60 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 21.43% | SVB Leerink | Joseph Schwartz64% | $33 → $34 | Maintains | Market Perform | Get Alert |
| 01/23/2023 | Buy Now | 17.86% | SVB Leerink | Mani Foroohar48% | $32 → $33 | Maintains | Market Perform | Get Alert |
| 01/19/2023 | Buy Now | 121.43% | Piper Sandler | Do Kim55% | $60 → $62 | Maintains | Overweight | Get Alert |
| 12/21/2022 | Buy Now | 42.86% | Morgan Stanley | Michael Ulz58% | $56 → $40 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/10/2022 | Buy Now | 100% | Morgan Stanley | Andrew Galler33% | $57 → $56 | Maintains | Overweight | Get Alert |
| 11/10/2022 | Buy Now | 10.71% | Citigroup | David Lebowitz52% | $28 → $31 | Maintains | Sell | Get Alert |
| 11/10/2022 | Buy Now | -7.14% | SVB Leerink | Mani Foroohar48% | $30 → $26 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 103.57% | Morgan Stanley | Andrew Galler33% | $30 → $57 | Upgrade | Underweight → Overweight | Get Alert |
| 08/10/2022 | Buy Now | — | Citigroup | David Lebowitz52% | $26 → $28 | Maintains | Sell | Get Alert |
| 08/10/2022 | Buy Now | 128.57% | RBC Capital | Luca Issi37% | $67 → $64 | Maintains | Outperform | Get Alert |
| 07/26/2022 | Buy Now | 107.14% | Piper Sandler | Do Kim55% | $55 → $58 | Maintains | Overweight | Get Alert |
| 07/18/2022 | Buy Now | 110.71% | Oppenheimer | Justin Kim37% | → $59 | Assumes | → Outperform | Get Alert |
| 06/21/2022 | Buy Now | -3.57% | SVB Leerink | Mani Foroohar48% | $26 → $27 | Maintains | Market Perform | Get Alert |
| 05/09/2022 | Buy Now | 7.14% | Morgan Stanley | David Lebowitz52% | $31 → $30 | Maintains | Underweight | Get Alert |
FAQ
What is the target price for Ionis Pharmaceuticals (IONS) stock?
The latest price target for Ionis Pharmaceuticals (NASDAQ:IONS) was reported by Needham on April 8, 2025. The analyst firm set a price target for $60.00 expecting IONS to rise to within 12 months (a possible 114.29% upside). 34 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ionis Pharmaceuticals (IONS)?
The latest analyst rating for Ionis Pharmaceuticals (NASDAQ:IONS) was provided by Needham, and Ionis Pharmaceuticals reiterated their buy rating.
When was the last upgrade for Ionis Pharmaceuticals (IONS)?
The last upgrade for Ionis Pharmaceuticals Inc happened on July 24, 2024 when Leerink Partners raised their price target to $62. Leerink Partners previously had a market perform for Ionis Pharmaceuticals Inc.
When was the last downgrade for Ionis Pharmaceuticals (IONS)?
The last downgrade for Ionis Pharmaceuticals Inc happened on August 2, 2024 when BMO Capital changed their price target from $67 to $60 for Ionis Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Ionis Pharmaceuticals (IONS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ionis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ionis Pharmaceuticals was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Ionis Pharmaceuticals (IONS) correct?
While ratings are subjective and will change, the latest Ionis Pharmaceuticals (IONS) rating was a reiterated with a price target of $60.00 to $60.00. The current price Ionis Pharmaceuticals (IONS) is trading at is $28.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.